Left Ventricular Mechanical Support with the Impella during Extracorporeal Membrane Oxygenation

Kasra Moazzami, MD, MPH\textsuperscript{1,2}, Elena V Dolmatova, MD\textsuperscript{1,2}, Thomas P Cocke, MD\textsuperscript{1,3}, Elie Elmann, MD\textsuperscript{1}, Pranay Vaidya, MD\textsuperscript{1}, Arthur F Ng, MD\textsuperscript{1}, Kumar Satya, MD\textsuperscript{1}, Rajeev L Narayan, MD, FACC, RPVI\textsuperscript{1,2,3*}

\textsuperscript{1}Hackensack University Medical Center, Hackensack, NJ, USA.  
\textsuperscript{2}Rutgers New Jersey Medical School, Newark, NJ, USA.  
\textsuperscript{3}Valley Medical Group and Valley Hospital, Ridgewood, NJ, USA.

Received 22 June 2016; Accepted 22 September 2016

Background: Venoarterial extracorporeal membrane oxygenation (ECMO) provides systemic arterial support without directly unloading the left heart, which causes an elevated left ventricular (LV) pressure. The aim of the present study was to investigate the adjunctive application of the Impella device for LV unloading in patients during ECMO.

Methods: This retrospective cohort study included patients who received Impella support in addition to venoarterial ECMO between April 2012 and December 2015. ECMO cannulation was performed peripherally or centrally, while the Impella device was surgically inserted into the femoral artery or the right axillary artery.

Results: Among 62 patients, 10 (16.1\%) received an Impella device during ECMO support. Following Impella support, right atrial pressure improved from a median of 18 (IQR, 14–24) mmHg to 13 (IQR, 10–15) mmHg and pulmonary wedge pressure improved from 30 (IQR, 26–35) mmHg to 16 (IQR, 12–19) mmHg in all the patients (p value < 0.001). Follow-up transthoracic echocardiograms (n = 6) showed a median decrease of 0.8 cm in LV end-diastolic volume (p value = 0.021). There were 5 (50\%) in-hospital deaths due to sustained brain injury (n = 3) and refractory cardiogenic shock (n = 2). The remaining 5 patients were discharged and successfully bridged to more permanent LV assist device (n = 2) or heart transplantation (n = 3).

Conclusion: The findings of the present study indicate that the application of the Impella device during ECMO support is effective in LV unloading and confers optimal hemodynamic support.

J Teh Univ Heart Ctr 2017;12(1):11-14

This paper should be cited as: Moazzami K, Dolmatova EV, Cocke TP, Elmann E, Vaidya P, Ng AF, Satya K, Narayan RL. Left Ventricular Mechanical Support with the Impella during Extracorporeal Membrane Oxygenation. J Teh Univ Heart Ctr 2017;12(1):11-14.

Keywords: Heart-assist devices • Extracorporeal membrane oxygenation • Heart ventricles • Treatment outcome
major advantages including feasibility of implantation, easy access, and cost-effectiveness compared to other circulatory devices. However, ECMO provides systemic arterial support without directly unloading the left heart. Therefore, despite the advantages of ECMO support, the inadequate unloading of the left ventricle (LV) could cause an elevated LV pressure. This in turn can increase myocardial wall stress and result in ischemia, delayed ventricular recovery, and eventually pulmonary venous hypertension and pulmonary edema.

The Impella device is a catheter-mounted microaxial pump capable of providing a continuous blood flow by draining it from the LV and delivering it to the aortic root. The device has been shown to provide short-term circulatory support by augmenting the cardiac output and unloading the LV in postcardiomyotomy heart failure or refractory cardiogenic shock settings.

The purpose of the present study was to present the results of the adjunctive application of the Impella device for LV unloading in patients during ECMO support.

**Methods**

In this retrospective cohort study, between April 2012 and December 2015, all patients who received venoarterial ECMO support in conjunction with Impella support during the same hospitalization at the Hackensack University Medical Center were recruited. Baseline characteristics including age, gender, body mass index, associated comorbidities, baseline ejection fraction, indications for ECMO and Impella support, and the total duration of ECMO duration were collected. An informed consent was obtained from all the patients. The study was approved by the institutional review board at the Hackensack University Medical Center.

Peripheral venoarterial ECMO (MAQUET Cardiopulmonary AG, Hirrlingen, Germany) was established through the femoral artery and the femoral vein under fluoroscopy guidance. The arterial cannula was placed in the distal aorta, proximal to the iliac bifurcation. The tip of the venous cannula was placed at the junction of the inferior vena cava and the right atrium. In addition, central ECMO cannulation was performed by using the left and right atria for access and positioning the outflow cannula into the ascending aorta.

The Impella 2.5 device (ABIOMED Europe GmbH, Aachen, Germany) was surgically inserted into the femoral artery or into the right axillary artery. The device was positioned across the aortic valve into the LV under the guidance of both fluoroscopy and transesophageal ultrasound.

All the data were analyzed using SPSS, version 18.0 (SPSS Inc., Chicago, IL, USA). The χ² test and the Mann–Whitney test were used for the categorical and continuous variables, respectively. All the continuous variables are presented as medians (interquartile ranges). A p value < 0.05 was considered significant.

**Results**

During the study period, a total of 62 patients received venoarterial ECMO support. Impella support was required in 10 (16.1%) patients. The median age of the cohort was 59 years (43–68), and 70.0% were male. All the baseline characteristics are summarized in Table 1. The indications

| Variable                      | All Patients (n=10) | Survivors (n=5) | Non-Survivors (n=5) | P value |
|-------------------------------|--------------------|-----------------|---------------------|---------|
| Median age (y)                | 59 [43-68]         | 53 [38-59]      | 64 [58-73]          | 0.241   |
| Male/Female                   | 7/3                | 3/4             | 4/3                 | 0.592   |
| Median BMI, (kg/m²)           | 29 [24-32]         | 27 [22-31]      | 30 [27-33]          | 0.213   |
| Comorbidities                 |                    |                 |                     |         |
| HTN                           | 7                  | 2               | 5                   | 0.182   |
| DM                            | 3                  | 1               | 2                   | 0.412   |
| CAD                           | 7                  | 3               | 4                   | 0.594   |
| CHF                           | 1                  | 0               | 1                   | 0.291   |
| CKD                           | 3                  | 0               | 3                   | 0.028   |
| Baseline EF (%)               | 20 [18-25]         | 20 [18-25]      | 19 [17-25 ]         | 0.866   |
| Indications for ECMO and Impella |                  |                 |                     |         |
| Cardiac arrest                | 6                  | 4               | 2                   | 0.246   |
| Cardiogenic shock             | 4                  | 1               | 3                   | 0.157   |
| ECMO duration (days)          | 6 [4-7]            | 6 [3-7]         | 6 [4-8]             | 0.891   |

*Data are presented as n or median (interquartile range)
BMI, Body mass index; HTN, Hypertension; DM, Diabetes mellitus; CAD, Coronary artery disease; CHF, Congestive heart failure; CKD, Chronic kidney disease; ECMO, Extracorporeal membrane oxygenation; EF, Ejection fraction
for ECMO and Impella support comprised shock post myocardial infarction in 4 patients, postcardiotomic cardiogenic shock in 3 patients, cardiogenic shock in the setting of chronic heart failure in 2 patients, and cardiogenic shock secondary to primary donor graft failure in 1 patient. Peripheral and central ECMO was established in 8 and 2 patients, respectively. The median duration of Impella and ECMO support was 1 (1–2.5) day and 6.5 (2–11.3) days, correspondingly. Among the survivors, the median duration of Impella support was 3 (2–5) days. Five patients received mechanical circulatory support via the intra-aortic balloon pump prior to ECMO and Impella support. Hypertension and coronary artery disease were the most common associated comorbidities in the entire cohort (70.0%) (Table 1). In 9 patients, hemodynamic stability was achieved from mechanical support provided by Impella and ECMO combination. Immediately following Impella support, right atrial pressure improved from a median of 18 (14–24) mmHg to 13 (10–15) mmHg and pulmonary wedge pressure improved from 30 (26–35) mmHg to 16 (12–19) mmHg in all the patients (p value < 0.001). Also, follow-up transthoracic echocardiography was done in 6 patients and showed a median decrease of 0.8 cm in LV end-diastolic volume (p value = 0.021).

There were 5 in-hospital deaths. No differences existed between the survivors and non-survivors in the baseline characteristics (Table 1), except for the incidence of chronic kidney disease. Among the non-survivors, 60.0% had a history of chronic kidney disease, while none of the survivors had a history of kidney disease (p value = 0.023). Among the non-survivors, 3 (60.0%) died as a result of severe neurological impairment. One patient developed a large ventricular septal defect after successful weaning from mechanical support and died of acute hemodynamic compromise. Another patient died from hemodynamic instability as a result of Impella device malfunction.

Clinically relevant adverse events occurred in 6 patients (3 survivors and 3 non-survivors). Four patients developed acute kidney injury; 3 of these patients required temporary renal replacement therapy. Major bleeding requiring transfusion occurred in 3 patients. In 1 patient, severe hemorrhage from the site of Impella implantation required the replacement of the Impella 2.5 with an Impella 5. Two patients also developed bacterial infections during mechanical support. As was mentioned earlier, fatal device malfunction occurred in 1 patient.

Successful ECMO and Impella weaning was achieved in 5 patients. Two patients were implanted with LV assist devices prior to discharge. The remaining 3 patients were transferred to another hospital to bridge to heart transplantation. No other major complications occurred during the first 28 days following discharge.

Discussion

The present study reports the clinical outcomes of Impella implantation in patients on ECMO support. The main finding of our study was a 50% survival rate in patients presenting with cardiac arrest and/or cardiogenic shock, with severe neurologic impairments accounting for 60% of mortality in non-survivors.

Among the adverse effects of ECMO on a failing heart is the inability to unload the LV. This can cause an increased LV pressure and LV distention, leading to pulmonary edema.8 In addition, the stasis associated with inadequate LV unloading could lead to thrombus formation within the LV cavity.15 A number of strategies have been suggested to decompress LV distention in patients on ECMO support including intra-aortic balloon pump, percutaneous atrial septostomy, central ECMO cannulation, and the Impella device.7, 16-19 The Impella device is an attractive alternative in this regard since it is implanted percutaneously without the need for surgical intervention. Also, the forward flow generated by the Impella could prevent potential LV stasis and thrombosis formation. Although only a limited number of studies have evaluated the efficacy of the Impella in patients on ECMO support, the results have been promising.17-22 In the present study, the combination of Impella and ECMO support was able to achieve hemodynamic stability in 9 out of 10 patients.

Major Impella device malfunction occurred in 1 patient in the present series, which led to severe hemodynamic instability and death. Device malfunction is among the most commonly seen complications of Impella implantation. It has been reported that up to 10% of Impella devices may experience malfunction and cause serious hemodynamic compromise.23, 24 Awareness of this potentially fatal complication as well as intraoperative strategies to prevent cardiovascular collapse is necessary in patients experiencing device malfunction.

Another major complication seen in the present study was bleeding, which required transfusion in 40% of the patients. As was previously described, the incidence of bleeding is high during venaarterial ECMO support, with some studies reporting up to 100% RBC transfusion requirement.24, 25 The main causes of bleeding include hemolysis and bleeding at the surgical site.

The main limitations of the present study are its low number of patients and retrospective, single-center nature. In addition, the present study was not a controlled trial with a comparison arm. Therefore, the results of the present study should be interpreted in the context of its limitations.

Conclusion

The present study indicates that the application of the Impella device during ECMO support is safe, feasible, and
effective in LV unloading and provides optimal hemodynamic support. Further studies are needed to confirm the clinical effectiveness of this approach in larger numbers of patients.

Acknowledgements

This study was approved and supported by the institutional review board of the Hackensack University Medical Center.

References

1. Kennedy JH. The role of assisted circulation in cardiac resuscitation. JAMA 1966;197:615-618.
2. Chen YS, Lin JW, Yu HY, Ko WJ, Jerger JS, Chang WT, Chen WJ, Huang SC, Chi NH, Wang CH, Chen LC, Tsai PR, Wang SS, Hwang JJ, Lin FY. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity score analysis. Lancet 2008;372:554-561.
3. Beutheret S, Mordant P, Paoletti X, Marijon E, Celermaijer DS, Léger P, Pavie A, Combes A, Leprince P. Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J 2013;34:112-120.
4. Chen JS, Ko WJ, Yu HY, Lai LP, Huang SC, Chi NH, Tsai CH, Wang SS, Lin FY, Chen YS. Analysis of the outcome for patients experiencing myocardial infarction and cardiopulmonary resuscitation refractory to conventional therapies necessitating extracorporeal life support rescue. Crit Care Med 2006;34:950-957.
5. Ventetuolo CE, Muratore CS. Extracorporeal life support in critically ill adults. Am J Respir Crit Care Med 2014;190:497-508.
6. Guizis M, Kumar M, Menkis AH, Freed DH. Minimally invasive left-heart decomposition during venoarterial extracorporeal membrane oxygenation: an alternative to a percutaneous approach. Interact Cardiovasc Thorac Surg 2010;10:672-674.
7. Aiyagari RM, Rocchini AP, Remenapp RT, Graziano JN. Decompression of the left atrium during extracorporeal membrane oxygenation using a transseptal cannula incorporated into the circuit. Crit Care Med 2006;34:2603-2606.
8. Soleimani B, Pae WE. Management of left ventricular distension during peripheral extracorporeal membrane oxygenation for cardiogenic shock. Perfusion 2012;27:326-331.
9. Strauer BE, Beer K, Heitlinger K, Höffling B. Left ventricular systolic wall stress as a primary determinant of myocardial oxygen consumption: comparative studies in patients with normal left ventricular function, with pressure and volume overload and with coronary heart disease. Basic Res Cardiol 1977;72:306-313.
10. Lucas SK, Schaff HV, Flaherty JT, Gott VL, Gardiner TJ. The harmful effects of ventricular distention during postischemic reperfusion. Ann Thorac Surg 1981;32:486-494.
11. Siegenthaler MP, Brehm K, Strecker T, Hanke T, Nötzdor A, Olschewski M, Weyand M, Sievers H, Beyersdorf F. The Impella Recover microaxial left ventricular assist device reduces mortality for postcardiotomy failure: a three-center experience. J Thorac Cardiovasc Surg 2004;127:812-822.
12. Meyns B, Dens J, Sergeant P, Herijgers P, Daenen W, Flameng W. Initial experiences with the Impella device in patients with cardiogenic shock - Impella support for cardiogenic shock. Thorac Cardiovasc Surg 2003;51:312-317.
13. Engström AE, Cocchieri R, Driessen AH, Sjaaw KD, Vis MM, Baan J, de Jong M, Lagrand WK, van der Sloot JA, Tijssen JG, de Winter RJ, de Mol BA, Piek JJ, Henriques JP. The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the Academic Medical Center intensive care unit experience. Crit Care Med 2011;39:2072-2079.
14. Kawashima D, Gojo S, Nishimura T, Itoda Y, Kitahori K, Moto mura N, Morota T, Murakami A, Takamoto S, Kyo S, Ono M. Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO J 2011;57:169-176.
15. Moubarak G, Weiss N, Leprince P, Luyt CE. Massive intraventricular thrombus complicating extracorporeal membrane oxygenation support. Can J Cardiol 2008;24:e1.
16. Avalli L, Maggioni E, Sangalli F, Favini G, Formica F, Fumagalli R. Percutaneous left-heart decompression during extracorporeal membrane oxygenation: an alternative to surgical and transeptal venting in adult patients. ASAIO J 2011;57:38-40.
17. Cheng A, Swartz MF, Massey HT. Impella to unload the left ventricle during peripheral extracorporeal membrane oxygenation. ASAIO J 2013;59:533-536.
18. Koeckert MS, Jorde UP, Naka Y, Moses JW, Takayama H. Impella LP 2.5 for left ventricular unloading during venaerial extracorporeal membrane oxygenation support. J Card Surg 2011;26:666-668.
19. Beutheret S, Mordant P, Pavie A, Leprince P. Impella and extracorporeal membrane oxygenation: a demanding combination. ASAIO J 2012;58:291-293.
20. Abu Saleh WK, Mason P, Jabbari OA, Samir H, Bruckner BA. Successful use of surgically placed impella 5.0 and central extracorporeal membrane oxygenation circuit in a patient with postcardiomyotony shock. Tex Heart Inst J 2015;42:569-571.
21. Chaparro SV, Badheka A, Marzouka GR, Tanawuttiwat T, Ahmed F, Sacher V, Pham SM. Combined use of Impella left ventricular assist device and extracorporeal membrane oxygenation as a bridge to recovery in fulminant myocarditis. ASAIO J 2012;58:285-287.
22. Pieri M, Contrri R, Winterton D, Montorfano M, Colombo A, Zan grillo A, De Bonis M, Pappalardo F. The contemporary role of Impella in a comprehensive mechanical circulatory support program: a single institutional experience. BMC Cardiovasc Disord 2015;15:126.
23. Lemaire A, Anderson MB, Lee LY, Scholz P, Prendergast T, Good man A, Lozano AM, Spotnitz A, Barsides G. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg 2014;97:133-138.
24. Gaudard P, Mourad M, Elet J, Zeroual N, Culas G, Rouvière P, Al bat B, Colson P. Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock. Crit Care 2015;19:363.
25. Loforte A, Montalto A, Ranocchi F, Della Monica PL, Casali G, Léger P, Pavie A, Combes A, Leprince P. Emergency circulatory support in refractory cardiogenic shock patients in remote institutions and 5.0 devices for ST-elevation myocardial infarction patients.